Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 5 | $2.42 | $2.96 | $2.63 |
Q2 2025 | 4 | $3.09 | $3.37 | $3.19 |
Q3 2025 | 4 | $3.13 | $3.41 | $3.24 |
Q4 2025 | 4 | $3.25 | $3.55 | $3.36 |
Q1 2026 | 3 | $2.77 | $3.02 | $2.86 |
Q2 2026 | 3 | $3.62 | $3.95 | $3.75 |
Q3 2026 | 3 | $3.58 | $3.91 | $3.71 |
Q4 2026 | 3 | $3.66 | $3.99 | $3.79 |
Q1 2027 | 3 | $2.75 | $3.00 | $2.85 |
Q2 2027 | 3 | $3.82 | $4.17 | $3.95 |
Q3 2027 | 3 | $3.49 | $3.81 | $3.61 |
Q4 2027 | 3 | $3.76 | $4.10 | $3.88 |
AbbVie Inc. last posted its earnings results on Wednesday, October 30th, 2024. The company reported $3 earnings per share for the quarter, topping analysts' consensus estimates of $2.92 by $0.08. The company had revenue of 14.46 B for the quarter and had revenue of 54.32 B for the year. AbbVie Inc. has generated $3 earnings per share over the last year ($2.72 diluted earnings per share) and currently has a price-to-earnings ratio of 60.63. AbbVie Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, January 31st, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/04/2024 | Q3 2024 | $0.88 | $14.28 B | $14.46 B | ||
08/07/2024 | Q2 2024 | $0.78 | $14.02 B | $14.46 B | ||
05/03/2024 | Q1 2024 | $0.77 | $12.31 B | |||
02/20/2024 | Q4 2023 | $0.46 | $14.30 B | |||
11/06/2023 | Q3 2023 | $1.00 | $13.72 B | $13.93 B | ||
08/07/2023 | Q2 2023 | $1.14 | $13.54 B | $13.87 B | ||
05/05/2023 | Q1 2023 | $0.13 | $12.23 B | |||
02/17/2023 | Q4 2022 | $1.40 | $15.12 B | |||
11/04/2022 | Q3 2022 | $2.23 | $14.96 B | $14.81 B | ||
08/04/2022 | Q2 2022 | $0.52 | $14.66 B | $14.58 B | ||
05/06/2022 | Q1 2022 | $2.54 | $13.54 B | |||
02/18/2022 | Q4 2021 | $2.29 | $14.89 B | |||
11/02/2021 | Q3 2021 | $1.78 | $14.30 B | $14.34 B | ||
08/02/2021 | Q2 2021 | $0.42 | $13.63 B | $13.96 B | ||
05/07/2021 | Q1 2021 | $2.00 | $13.01 B | |||
02/19/2021 | Q4 2020 | $0.02 | $13.86 B | |||
11/04/2020 | Q3 2020 | $1.30 | $12.72 B | $12.90 B | ||
08/04/2020 | Q2 2020 | -$0.45 | $9.94 B | $10.43 B | ||
05/07/2020 | Q1 2020 | $2.02 | $8.62 B | |||
02/21/2020 | Q4 2019 | $1.89 | $8.70 B |
AbbVie Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, January 31st, 2025 based off last year's report dates.
In the previous quarter, AbbVie Inc. (:ABBV) reported $3 earnings per share (EPS) to beat the analysts' consensus estimate of $2.92 by $0.08.
The conference call for AbbVie Inc.'s latest earnings report can be listened to online.
The conference call transcript for AbbVie Inc.'s latest earnings report can be read online.
AbbVie Inc. (:ABBV) has a recorded annual revenue of $54.32 B.
AbbVie Inc. (:ABBV) has a recorded net income of $54.32 B. AbbVie Inc. has generated $2.73 earnings per share over the last four quarters.
AbbVie Inc. (:ABBV) has a price-to-earnings ratio of 60.63 and price/earnings-to-growth ratio is -15.21.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED